Bailard Inc. Buys Shares of 2,901 Clorox Co (CLX)

Share on StockTwits

Bailard Inc. bought a new position in Clorox Co (NYSE:CLX) during the fourth quarter, HoldingsChannel reports. The fund bought 2,901 shares of the company’s stock, valued at approximately $447,000.

A number of other hedge funds also recently modified their holdings of CLX. Parsons Capital Management Inc. RI lifted its position in Clorox by 0.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 9,538 shares of the company’s stock valued at $1,470,000 after acquiring an additional 70 shares during the last quarter. DAVENPORT & Co LLC raised its holdings in shares of Clorox by 1.2% in the fourth quarter. DAVENPORT & Co LLC now owns 6,611 shares of the company’s stock worth $1,019,000 after buying an additional 80 shares during the last quarter. G&S Capital LLC raised its holdings in shares of Clorox by 46.4% in the fourth quarter. G&S Capital LLC now owns 262 shares of the company’s stock worth $40,000 after buying an additional 83 shares during the last quarter. Eads & Heald Wealth Management raised its holdings in shares of Clorox by 1.4% in the fourth quarter. Eads & Heald Wealth Management now owns 5,963 shares of the company’s stock worth $919,000 after buying an additional 84 shares during the last quarter. Finally, Tdam USA Inc. raised its holdings in shares of Clorox by 1.6% in the fourth quarter. Tdam USA Inc. now owns 5,628 shares of the company’s stock worth $867,000 after buying an additional 86 shares during the last quarter. Institutional investors and hedge funds own 82.60% of the company’s stock.

A number of research analysts have issued reports on CLX shares. Zacks Investment Research cut shares of Clorox from a “hold” rating to a “sell” rating in a report on Monday, December 31st. BMO Capital Markets set a $175.00 price target on shares of Clorox and gave the stock a “buy” rating in a report on Tuesday, February 5th. Citigroup raised their price target on shares of Clorox from $149.00 to $153.00 and gave the stock a “neutral” rating in a report on Friday, November 2nd. Barclays reaffirmed a “hold” rating and issued a $142.00 price target on shares of Clorox in a report on Wednesday, February 6th. Finally, Deutsche Bank raised their price target on shares of Clorox from $123.00 to $124.00 and gave the stock a “sell” rating in a report on Thursday, November 1st. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $149.08.

In other news, CEO Benno O. Dorer sold 152,449 shares of the stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $164.83, for a total value of $25,128,168.67. Following the sale, the chief executive officer now owns 111,735 shares in the company, valued at $18,417,280.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Dawn C. Willoughby sold 25,950 shares of the stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $164.59, for a total transaction of $4,271,110.50. Following the completion of the sale, the chief operating officer now owns 32,409 shares in the company, valued at approximately $5,334,197.31. The disclosure for this sale can be found here. Insiders sold 249,846 shares of company stock worth $40,871,653 in the last quarter. Company insiders own 1.40% of the company’s stock.

NYSE:CLX opened at $156.31 on Thursday. The firm has a market capitalization of $19.95 billion, a PE ratio of 24.97, a price-to-earnings-growth ratio of 3.86 and a beta of 0.29. Clorox Co has a 1-year low of $113.57 and a 1-year high of $167.70. The company has a current ratio of 1.15, a quick ratio of 0.66 and a debt-to-equity ratio of 3.08.

Clorox (NYSE:CLX) last released its quarterly earnings data on Monday, February 4th. The company reported $1.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.08. The firm had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.47 billion. Clorox had a net margin of 12.65% and a return on equity of 105.97%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.77 earnings per share. Research analysts predict that Clorox Co will post 6.33 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Bailard Inc. Buys Shares of 2,901 Clorox Co (CLX)” was originally reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/2019/02/14/bailard-inc-buys-shares-of-2901-clorox-co-clx/3214744.html.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Story: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.